Kawasaki syndrome (the mucocutaneous lymph node syndrome).
Kawasaki Syndrome is a newly recognized clinical entity characterized by multisystem involvement. It has an acute onset and a triphasic clinical course. Although essentially a self-limited disease, permanent vascular damage, especially involving the coronary arteries, may result. Pathologically the disease is characterized by widespread vasculitis. There is a monomodal age distribution with peak occurrence during the first 2 years of life; few affected over the age of 8 years. Males outnumber females 1.5:1, persons of Japanese extraction are overrepresented compared with other races, and Caucasians are underrepresented. Community-wide epidemics occur in diverse locations but there is no evidence for direct person-to-person transmission. Etiology remains unknown. Therapy remains supportive and should be directed at careful clinical evaluation for cardiovascular abnormalities and antiplatelet aggregation therapy.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001168:Arthritis / Q000175:diagnosis; D001241:Aspirin / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D005334:Fever / Q000175:diagnosis; D006254:Hawaii; D006331:Heart Diseases / Q000175:diagnosis; D006801:Humans; D007223:Infant; D007564:Japan; D008206:Lymphatic Diseases; D008297:Male; D008582:Meningitis, Aseptic / Q000175:diagnosis; D009080:Mucocutaneous Lymph Node Syndrome / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D011776:Pyuria / Q000175:diagnosis
D000305:Adrenal Cortex Hormones; D001241:Aspirin